Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899811 | 0.83 | SIGMAR1 (0.50) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL2472922 | 0.82 | TAAR1 (0.50) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL5594577 | 0.82 | SIGMAR1 (0.48) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL2480450 | 0.79 | TAAR1 (0.47) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL17802435 | 0.78 | SIGMAR1 (0.50) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL2477572 | 0.78 | SIGMAR1 (0.50) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL28420192 | 0.78 | MAOA (0.48) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL367519 | 0.78 | TRPA1 (0.48) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| SCHEMBL6387963 | 0.74 | SIGMAR1 (0.54) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL1560962 | 0.73 | SLC6A2 (1.00) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4410998-B1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING THE PROGRESSION RATE OF PARKINSON'S DISEASE | ST JOHNS UNIV (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062753-A1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | ST JOHNS UNIV (US) | 2026-03-05 | — | — | US | disclosed |
| US-12448653-B2 | Circulating serum microRNA biomarkers and methods for Parkinson's disease prognosis | ST. JOHN'S UNIVERSITY (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4410998-A2 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING THE PROGRESSION RATE OF PARKINSON'S DISEASE | St. John's University (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3988674-B1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING THE PROGRESSION RATE OF PARKINSON'S DISEASE | ST JOHNS UNIV (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240018595-A1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | ST JOHNS UNIV (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230323442-A1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS | ST JOHNS UNIV (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3411500-B9 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING PARKINSON'S DISEASE | ST JOHNS UNIV (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11739384-B2 | Circulating serum microRNA biomarkers and methods for Parkinson's disease prognosis | ST. JOHN'S UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3411500-B1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING PARKINSON'S DISEASE | ST JOHNS UNIV (US) | 2023-06-07 | — | — | EP | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| EP-2070526-B1 | Methods for treatment of Parkinson's disease | NEWRON PHARM SPA (IT) | 2014-02-26 | — | — | EP | disclosed |
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-02-28 | — | — | US | disclosed |
| US-8283380-B2 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-09 | — | — | US | disclosed |
| US-20100286124-A1 | PROP-2-YN-1-AMINE INHIBITORS OF MONOAMINE OXIDASE TYPE B | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-1613296-B1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARM SPA (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-7390847-B2 | Polymer derivatives for the treatment of metals | BASF SE (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| US-20050121114-A1 | Polymer derivatives for the treatment of metals | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | MAOB, MAOA, SNCA | TAAR1 723/4885SLC6A2 407/4885SIGMAR1 1027/4885 |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | TAAR1 723/4885SLC6A2 407/4885SIGMAR1 1027/4885 |
| US-20100286124-A1 | PROP-2-YN-1-AMINE INHIBITORS OF MONOAMINE OXIDASE TYPE B | MAOB, MAOA, TYR | TAAR1 538/4885SLC6A2 130/4885SIGMAR1 1027/4885 |
| US-20260062753-A1 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | COMT, DAO, TH | TAAR1 412/4885SLC6A2 63/4885SIGMAR1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.